Related Experiment Video
Updated: May 22, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Lurasidone (latuda®): an atypical antipsychotic
Shambria F Nolan1, Marian W Roman
1The University of Tennessee Health Sciences Center, Memphis, TN, USA.
Issues in Mental Health Nursing
|May 2, 2012
Summary
Lurasidone, an atypical antipsychotic, shows efficacy in treating schizophrenia symptoms, including negative and cognitive aspects. It offers good tolerability and cardiovascular safety without significant metabolic side effects.
Area of Science:
- Pharmacology
- Psychiatry
- Neuroscience
Background:
- Schizophrenia presents complex challenges, including psychosis, mood, and cognitive deficits.
- Existing atypical antipsychotics have varying efficacy and side effect profiles.
- Negative symptoms and cognitive impairment remain difficult to treat effectively.
Purpose of the Study:
- To evaluate the efficacy and safety of lurasidone for schizophrenia treatment.
- To explore lurasidone's potential advantages in addressing negative and cognitive symptoms.
- To assess lurasidone's metabolic and cardiovascular tolerability.
Main Methods:
- Clinical trials assessing lurasidone's effects on psychotic, mood, and cognitive symptoms.
- Comparative analysis of lurasidone's side effect profile against other atypical antipsychotics.
- Evaluation of metabolic parameters (weight, glucose, lipids) and cardiovascular safety (QT interval).
Main Results:
- Lurasidone demonstrated positive effects on psychosis, mood, and cognition in schizophrenia patients.
- Its tolerability profile appears comparable to existing atypical antipsychotics.
- No significant adverse impact on metabolic profiles or QT interval widening was observed.
Conclusions:
- Lurasidone presents a favorable efficacy and safety profile for schizophrenia treatment.
- Its potent 5-HT7 receptor blockade may offer benefits for negative and cognitive symptoms.
- Lurasidone is a potential therapeutic option, especially for patients with endocrine or cardiovascular concerns.
Related Concept Videos
01:21Antipsychotic Drugs: Typical and Atypical Agents
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: